Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Work
Year: 2014
Type: article
Abstract: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lu... more
Source: New England Journal of Medicine
Institutions University of Southampton, National Institute for Health Research, NIHR Southampton Respiratory Biomedical Research Unit, Imperial College London, Seattle University +22 more
Cites: 21
Cited by: 3,760
Related to: 10
FWCI: 247
Citation percentile (by year/subfield): 100
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze